Philadelphia Pharmaceuticals Company (ASE:PHIL)
Jordan · Delayed Price · Currency is JOD 2.000
+0.010 (0.50%)
At close: Jul 30, 2026
ASE:PHIL Income Statement
Financials in millions JOD. Fiscal year is January - December.
Millions JOD. Fiscal year is Jan - Dec.
Fiscal Year | TTM | FY 2025 | FY 2024 | FY 2023 | FY 2022 | FY 2021 |
|---|---|---|---|---|---|---|
Period Ending | Jun '26 Jun 30, 2026 | Dec '25 Dec 31, 2025 | Dec '24 Dec 31, 2024 | Dec '23 Dec 31, 2023 | Dec '22 Dec 31, 2022 | Dec '21 Dec 31, 2021 |
| 8.97 | 9.17 | 8.76 | 8.4 | 8.42 | 6.6 | |
Revenue Growth | -2.34% | 4.64% | 4.25% | -0.12% | 27.48% | -13.77% |
Cost of Revenue | 4.53 | 4.66 | 4.64 | 4.4 | 4.51 | 3.47 |
Gross Profit | 4.44 | 4.51 | 4.12 | 4 | 3.91 | 3.13 |
Selling, General & Admin | 2.49 | 2.52 | 2.3 | 2.21 | 2.59 | 2.41 |
Research & Development | 0.43 | 0.45 | 0.42 | 0.44 | 0.22 | - |
Operating Expenses | 2.92 | 2.97 | 2.72 | 2.65 | 2.81 | 2.41 |
Operating Income | 1.52 | 1.54 | 1.4 | 1.35 | 1.1 | 0.72 |
Interest Expense | -0.3 | -0.29 | -0.35 | -0.34 | -0.24 | -0.23 |
Other Non Operating Income (Expenses) | 0.01 | 0.03 | -0 | 0 | 0 | 0.01 |
EBT Excluding Unusual Items | 1.23 | 1.27 | 1.04 | 1.02 | 0.87 | 0.49 |
Pretax Income | 1.23 | 1.27 | 1.04 | 1.02 | 0.87 | 0.49 |
Income Tax Expense | 0.17 | 0.27 | 0.22 | 0.21 | 0.16 | 0.08 |
Net Income | 1.06 | 1.01 | 0.82 | 0.81 | 0.7 | 0.41 |
Net Income to Common | 1.06 | 1.01 | 0.82 | 0.81 | 0.7 | 0.41 |
Net Income Growth | 15.93% | 22.35% | 1.77% | 15.13% | 70.91% | 189.48% |
Shares Outstanding (Basic) | 8 | 8 | 8 | 8 | 8 | 8 |
Shares Outstanding (Diluted) | 8 | 8 | 8 | 8 | 8 | 8 |
Shares Change | - | - | - | - | - | - |
EPS (Basic) | 0.14 | 0.13 | 0.11 | 0.11 | 0.09 | 0.05 |
EPS (Diluted) | 0.14 | 0.13 | 0.11 | 0.11 | 0.09 | 0.05 |
EPS Growth | 15.93% | 22.35% | 1.77% | 15.13% | 70.91% | 189.49% |
Additional Metrics
Fiscal Year | TTM | FY 2025 | FY 2024 | FY 2023 | FY 2022 | FY 2021 |
|---|---|---|---|---|---|---|
Period Ending | Jun '26 Jun 30, 2026 | Dec '25 Dec 31, 2025 | Dec '24 Dec 31, 2024 | Dec '23 Dec 31, 2023 | Dec '22 Dec 31, 2022 | Dec '21 Dec 31, 2021 |
Free Cash Flow | 0.88 | 1.16 | 1.53 | 1.03 | 1.94 | 2.94 |
Free Cash Flow Per Share | 0.12 | 0.15 | 0.20 | 0.14 | 0.26 | 0.39 |
Dividend Per Share | - | - | 0.070 | 0.070 | 0.060 | 0.060 |
Dividend Growth | - | - | 0% | 16.67% | 0% | - |
Gross Margin | 49.48% | 49.16% | 47.03% | 47.64% | 46.42% | 47.47% |
Operating Margin | 16.97% | 16.77% | 15.94% | 16.12% | 13.05% | 10.90% |
Profit Margin | 11.82% | 10.96% | 9.38% | 9.60% | 8.33% | 6.21% |
Free Cash Flow Margin | 9.85% | 12.63% | 17.43% | 12.30% | 23.07% | 44.57% |
EBITDA | 1.62 | 1.78 | 1.67 | 1.65 | 1.22 | 0.88 |
EBITDA Margin | 18.03% | 19.40% | 19.08% | 19.62% | 14.48% | 13.32% |
D&A For EBITDA | 0.1 | 0.24 | 0.28 | 0.29 | 0.12 | 0.16 |
EBIT | 1.52 | 1.54 | 1.4 | 1.35 | 1.1 | 0.72 |
EBIT Margin | 16.97% | 16.77% | 15.94% | 16.12% | 13.05% | 10.90% |
Effective Tax Rate | 13.69% | 21.00% | 21.03% | 21.02% | 19.00% | 16.94% |
Advertising Expenses | - | 0.31 | 0.24 | - | 0.21 | 0.2 |